Humoral immunity in reconvalescents and persons vaccinated against COVID-19: a comparative assessment of the main indices of the humoral immune response
- Authors: Karimov I.F.1, Korneev A.G.1, Borisov S.D.1, Nosyreva S.Y.1, Ushakova A.A.1, Pankova A.A.1, Pankov A.S.1
-
Affiliations:
- Orenburg State Medical University
- Issue: Vol 25, No 2 (2022)
- Pages: 187-194
- Section: SHORT COMMUNICATIONS
- URL: https://journals.rcsi.science/1028-7221/article/view/120181
- DOI: https://doi.org/10.46235/1028-7221-1105-HII
- ID: 120181
Cite item
Full Text
Abstract
Specific humoral immunity to SARS-CoV-2 develops due to the formation of neutralizing IgG, which can primarily block the receptor-binding domain of the viral S-protein. The duration of post-infection immunity, as well as avidity of circulating antibodies, play an important role in this process. The aim of this work was to evaluate the amounts of antibodies to SARS-CoV 2 S-protein, their avidity and neutralizing activity in the studied samples of the post-COVID patients versus vaccinated seropositive individuals. Materials and methods. A sample of 113 individuals was studied, which consisted of three experimental groups, i.e.: recovered, vaccinated, as well as recovered and vaccinated persons. Blood serum specimens of the individuals were studied for specific IgG to SARS-CoV-2, along with determination of their quantities (BAU/mL) using Vector-Best kits (Novosibirsk, Russia). The avidity index was determined using a kit manufactured by MedipalTech (Dubna, Russia). Neutralizing ability of the antibodies was assayed by means of ELISA with diagnostic kits from MedipalTech (Dubna, Russia), which resulted into percentage of neutralized S-proteins to RBD. Results. The average levels of IgG did not show significant differences between reconvalescents and vaccinated persons. However, both indicators were significantly lower than those from the groups who recovered from the disease and were vaccinated. A cyclic change in the numbers of antibodies was observed, along with most intensive drop in the level of immunoglobulins over first four months after the illness or vaccination. Despite initially similar levels of immune parameters in both groups, the decline of this index in “vaccinated” group was significantly higher than in the “recovered” group, thus allowing us to conclude that the amounts of specific antibodies in this group was shown to be decreased to zero levels as soon as by the 10th month. IgG index among the «recovered and vaccinated» groups remained unchanged for the entire anamnestic period. Avidity index of the antibodies in vaccinated individuals was higher than in recovered individuals. Meanwhile, this index in both groups was characterized by stable increase over the observation period of 7 to 11 months. The highest levels of antibodies and their avidity were noted in the group of recovered and vaccinated individuals, due to the most complete activation of the immune system. A straight-line trend was revealed for the decreasing index of neutralizing activity during the considered time period. The overall pattern of thee results shows that the neutralizing activity of antibodies is largely determined by the amounts of SARS-CoV-2-specific immunoglobulins. Thus, the time dynamics of antibodies to SARS-CoV-2 in various groups of examined individuals was revealed. Direct correlation was established between the neutralizing activity and amounts of immunoglobulins, as well as the role of vaccination for increased avidity of antibodies.
Full Text
##article.viewOnOriginalSite##About the authors
Ilshat F. Karimov
Orenburg State Medical University
Author for correspondence.
Email: ifkarimov@yandex.ru
ORCID iD: 0000-0001-6853-4242
SPIN-code: 2898-9150
Scopus Author ID: 26650061100
ResearcherId: F-2041-2015
PhD (Biology), Laboratory of Microbiology, Research Center, Associate Professor, Department of Microbiology
Russian Federation, 5, Sharlyk highway, Orenburg, 460048Alexey G. Korneev
Orenburg State Medical University
Email: proletela@mail.ru
ORCID iD: 0000-0002-7574-0527
PhD (Biology), Associate Professor, Department of Epidemiology and Infectious Diseases
Russian Federation, OrenburgSergey D. Borisov
Orenburg State Medical University
Email: sdborisov56@mail.ru
ORCID iD: 0000-0002-4386-8745
PhD (Medicine), Honored Doctor of the Russian Federation, Head, Laboratory of Microbiology, Research Center, Associate Professor, Department of Microbiology, Virology, Immunology
Russian Federation, OrenburgSvetlana Yu. Nosyreva
Orenburg State Medical University
Email: swet1212@yandex.ru
ORCID iD: 0000-0002-2758-7388
PhD (Medicine), Associate Professor, Department of Epidemiology and Infectious Diseases, Clinical Virologist, Research Center
Russian Federation, OrenburgAnastasia A. Ushakova
Orenburg State Medical University
Email: mjasoed.na@inbox.ru
Assistant Professor, Department of Epidemiology and Infectious Diseases
Russian Federation, OrenburgAnna A. Pankova
Orenburg State Medical University
Email: pankovaaa@mail.ru
Student, Medical Faculty
Russian Federation, OrenburgAlexandr S. Pankov
Orenburg State Medical University
Email: aspan751@mail.ru
ORCID iD: 0000-0003-4994-6633
PhD, MD (Medicine), Associate Professor, Head, Department of Epidemiology and Infectious Diseases, Director, Research Center
Russian Federation, OrenburgReferences
- Носырева С.Ю., Паньков А.С., Корнеев А.Г. Новая коронавирусная инфекция (COVID-19) у детей: клинико-лабораторные и диагностические аспекты // Детские инфекции, 2021. Т. 20, № 3. С. 23-28. [Nosyreva S.Yu., Pankov A.S., Korneev A.G. New coronavirus infection (COVID-19) in children: clinical, laboratory and diagnostic aspects. Detskiye infekcii = Children’s Infections, 2021, Vol. 20, no. 3, pp. 23-28. (In Russ.)]
- Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. Int. J. Infect. Dis., 2021, Vol. 106, pp. 61-64.
- Benner S.E., Patel E.U., Laeyendecker O., Pekosz A., Littlefield K., Eby Y., Fernandez R.E., Miller J., Kirby C.S., Keruly M., Klock E., Baker O.R., Schmidt H.A., Shrestha R., Burgess I., Bonny T.S., Clarke W., Caturegli P., Sullivan D., Shoham S., Quinn T.C., Bloch E.M., Casadevall A., Tobian A.A.R., Redd A.D. SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors. J. Infect. Dis., 2020, Vol. 222, no. 12, pp. 1974-1984.
- Cascella M., Rajnik M., Aleem A., Dulebohn S.C., di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19) [Updated 2022 Feb 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan.
- Dan J.M., Mateus J., Kato Y., Hastie K.M., Yu E.D., Faliti C.E., Grifoni A., Ramirez S.I., Haupt S., Frazier A., Nakao C., Rayaprolu V., Rawlings S.A., Peters B., Krammer F., Simon V., Saphire E.O., Smith D.M., Weiskopf D., Sette A., Crotty S. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science, 2021, Vol. 371, no. 6529, eabf4063. doi: 10.1126/science.abf4063.
- Esakandari H., Nabi-Afjadi M., Fakkari-Afjadi J., Farahmandian N., Miresmaeili S.M., Bahreini E. A comprehensive review of COVID-19 characteristics. Biol. Proced. Online, 2020, Vol. 22, 19. doi: 10.1186/s12575-020-00128-2.
- Grigoryan L., Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. Semin. Immunol., 2020, Vol. 50, 101422. doi: 10.1016/j.smim.2020.101422.
- Jain R., Mallya M.V., Amoncar S., Palyekar S., Adsul H.P., Kumar R., Chawla S. Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India. Transfus. Clin. Biol., 2022, Vol. 29, no. 1, pp. 60-64.
- Kaur S.P., Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res., 2020, Vol. 288, 198114. doi: 10.1016/j.virusres.2020.198114.
- Longueira Y., Polo M.L.; InViV working group; Biobanco de Enfermedades Infecciosas Colección COVID19 working group, Turk G, Laufer N. Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina. Heliyon, 2021, Vol. 7, no. 10, e08140. doi: 10.1016/j.heliyon.2021.e08140.
- Luo C., Liu M., Li Q., Zheng X., Ai W., Gong F., Fan J., Liu S., Wang X., Luo J. Dynamic changes and prevalence of SARS-CoV-2 IgG/IgM antibodies: Analysis of multiple factors. Int. J. Infect. Dis., 2021, Vol. 108, pp. 57-62.
- Mahajan A., Manchikanti L. Value and validity of coronavirus antibody testing. Pain Physician, 2020, Vol. 23, no. 4S, pp. S381-S390.
- Moura A.D., da Costa H.H.M., Correa V.A., de S Lima A.K., Lindoso J.A.L., De Gaspari E., Hong M.A., Cunha-Junior J.P., Prudencio C.R. Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients. Sci. Rep., 2021, Vol. 11, no. 1, 17642. doi: 10.1038/s41598-021-95045-z.
- Sun B., Feng Y., Mo X., Zheng P., Wang Q., Li P., Peng P., Liu X., Chen Z., Huang H., Zhang F., Luo W., Niu X., Hu P., Wang L., Peng H., Huang Z., Feng L., Li F., Zhang F., Chen L. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg. Microbes Infect., 2020, Vol. 9, no. 1, pp. 940-948.
- Wu C., Liu Y., Yang Y., Zhang P., Zhong W., Wang Y., Wang Q., Xu Y., Li M., Li X., Zheng M., Chen L., Li H. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B., 2020, Vol. 10, no. 5, pp. 766-788.